TY  - GEN
AU  - Karp,Judith E
AU  - Garrett-Mayer,Elizabeth
AU  - Estey,Elihu H
AU  - Rudek,Michelle A
AU  - Smith,B Douglas
AU  - Greer,Jacqueline M
AU  - Drye,D Michelle
AU  - Mackey,Karen
AU  - Dorcy,Kathleen Shannon
AU  - Gore,Steven D
AU  - Levis,Mark J
AU  - McDevitt,Michael A
AU  - Carraway,Hetty E
AU  - Pratz,Keith W
AU  - Gladstone,Douglas E
AU  - Showel,Margaret M
AU  - Othus,Megan
AU  - Doyle,L Austin
AU  - Wright,John J
AU  - Pagel,John M
TI  - Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia
SN  - 1592-8721
PY  - 2013///1107
KW  - Adult
KW  - Aged
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - administration & dosage
KW  - Cytarabine
KW  - Disease-Free Survival
KW  - Female
KW  - Flavonoids
KW  - Humans
KW  - Leukemia, Myeloid, Acute
KW  - drug therapy
KW  - Male
KW  - Middle Aged
KW  - Mitoxantrone
KW  - Piperidines
KW  - Survival Rate
N1  - Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.3324/haematol.2012.062539
ER  -